Omicron Half as Likely as Delta to Lead to Long COVID: Study

People who were vaccinated at least six months prior to infection had the lowest risk of lasting symptoms in a UK study.

Written byChristie Wilcox, PhD
| 2 min read
hourglass with coronaviruses instead of sand
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Self-reported data from nearly 100,000 people in the UK indicate that COVID-19 cases caused by the Delta variant were 2.4 times more likely to result in long COVID than those caused by Omicron. The research, published online yesterday (June 16) as a letter in The Lancet, claims to be the first large-scale study to examine the risk of developing long COVID from an Omicron infection.

The data came from the COVID Symptom Study app, which is run by King’s College London researchers and allows people to report symptoms and test results. In all, the researchers obtained data from 56,003 people who tested positive for COVID-19 during the Omicron wave (defined by the researchers as December 20, 2021–March 9, 2022) and 41,361 who tested positive during the Delta wave (June 1, 2021–November 27, 2021). Participants were considered to have long COVID if they reported symptoms such as fatigue, brain fog, or ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies